Alimera Sciences Inc (ALIM)

1.38
NASDAQ : Health Care
Prev Close 1.29
Day Low/High 1.30 / 1.39
52 Wk Low/High 1.03 / 1.72
Avg Volume 252.30K
Exchange NASDAQ
Shares Outstanding 69.05M
Market Cap 89.77M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Alimera Sciences Announces 9 Clinical Presentations And A Sponsored Symposium At 17th Euretina Congress

Alimera Sciences Announces 9 Clinical Presentations And A Sponsored Symposium At 17th Euretina Congress

20 electronic posters available for review as well

Alimera Sciences Signs Agreement For Exclusive Distributor Of ILUVIEN® In France

Alimera Sciences Signs Agreement For Exclusive Distributor Of ILUVIEN® In France

Horus Pharma S.A.S. to also serve as agent in price negotiations with French Regulatory Authorities

Alimera Sciences Announces Italian Patients Now Being Treated With ILUVIEN®

Alimera Sciences Announces Italian Patients Now Being Treated With ILUVIEN®

ILUVIEN is fully reimbursable as a hospital-administered therapy in Italy

Alimera Sciences To Expand ILUVIEN® Indication In Europe For Posterior Uveitis

Alimera Sciences To Expand ILUVIEN® Indication In Europe For Posterior Uveitis

Signs license agreement with pSivida for posterior uveitis in Europe, the Middle East and Africa

Alimera Sciences Announces The Reimbursement Of ILUVIEN® In Italy

ILUVIEN is fully reimbursable as a hospital-administered therapy in Italy

Alimera Sciences Begins Selling ILUVIEN® In The Middle East

Alimera Sciences Begins Selling ILUVIEN® In The Middle East

First DME patient in the region has received treatment

First Week of November 18th Options Trading For Alimera Sciences (ALIM)

First Week of November 18th Options Trading For Alimera Sciences (ALIM)

Investors in Alimera Sciences, Inc. saw new options become available this week, for the November 18th expiration.

TheStreet Quant Rating: D- (Sell)